tert-butyl 4-(2-methoxyphenyl)piperazine-1-carboxylate | 95520-98-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(2-methoxyphenyl)piperazine-1-carboxylate
• CAS: 95520-98-2
• 化学式: C₁₆H₂₄N₂O₃
• 分子量: 292.378
• InChiKey: DJWNFMMYIQIDBH-UHFFFAOYSA-N

物化性质

• 熔点：
  68-69 °C
• 沸点：
  409.0±40.0 °C(Predicted)
• 密度：
  1.107±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2-methoxyphenyl)piperazine-1-carboxylate 在 盐酸 作用下， 以 乙醚 为溶剂， 反应 2.0h， 以90.08%的产率得到1-(2-methoxyphenyl)piperazine hydrochloride
  参考文献：
  名称：

  [EN] THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION
  [FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS DESTINÉS AU TRAITEMENT D'UN CANCER CARACTÉRISÉ PAR UNE MUTATION IDH

  摘要：

  本文描述了用于治疗癌症的化合物和组合物。这些化合物和组合物可用于调节具有α-羟基新活性的异柠檬酸脱氢酶（IDH）突变体（例如IDH1m或IDH2m）。

  公开号：

  WO2011072174A1
• 作为产物：
  描述：

  苯甲醚 在 正丁基锂 、 copper dichloride 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.3h， 生成 tert-butyl 4-(2-methoxyphenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Copper-Catalyzed Electrophilic Amination of Heteroarenes via C–H Alumination

  摘要：

  A highly efficient Cu-catalyzed electrophilic amination reaction of readily available heteroarenes with O-benzoyl hydroxylamines via a one-pot C-H alumination is reported. The reactions were catalyzed using 1 mol % of CuCl to afford various heteroaryl amines in good to excellent yields. The direct C-H lithiation/transalumination of heteroarenes and catalytic amination sequence can be performed in a single vessel on gram scales.

  DOI：

  10.1021/acs.joc.5b01863

文献信息

• Mild deprotection of the <i>N-tert</i>-butyloxycarbonyl (<i>N</i>-Boc) group using oxalyl chloride
  作者：Nathaniel George、Samuel Ofori、Sean Parkin、Samuel G. Awuah

  DOI：10.1039/d0ra04110f

  日期：——

  We report a mild method for the selective deprotection of the N-Boc group from a structurally diverse set of compounds, encompassing aliphatic, aromatic, and heterocyclic substrates by using oxalyl chloride in methanol. The reactions take place under room temperature conditions for 1–4 h with yields up to 90%. This mild procedure was applied to a hybrid, medicinally active compound FC1, which is a

  我们报告了一种温和的方法，通过在甲醇中使用草酰氯，从结构多样的一组化合物（包括脂肪族、芳香族和杂环底物）中选择性脱保护N -Boc 基团。反应在室温条件下进行 1-4 小时，产率高达 90%。这种温和的程序应用于一种混合的药用活性化合物 FC1，它是一种新型的 IDO1 和 DNA Pol γ 双重抑制剂。对于这种去保护策略，假设了涉及草酰氯的亲电特性的更广泛的机制。
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：Salituro Francesco G.

  公开号：US20100331307A1

  公开（公告）日：2010-12-30

  Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

  本文描述了调节丙酮酸激酶M2（PKM2）的化合物和含有这些化合物的组合物。本文还描述了利用调节PKM2的化合物治疗癌症的方法。
• Design and preparation of new palladium precatalysts for C–C and C–N cross-coupling reactions
  作者：Nicholas C. Bruno、Matthew T. Tudge、Stephen L. Buchwald

  DOI：10.1039/c2sc20903a

  日期：——

  of easily prepared, phosphine-ligated palladium precatalysts based on the 2-aminobiphenyl scaffold have been prepared. The role of the precatalyst-associated labile halide (or pseudohalide) in the formation and stability of the palladacycle has been examined. It was found that replacing the chloride in the previous version of the precatalyst with a mesylate leads to a new class of precatalysts with

  已经制备了一系列基于 2-氨基联苯支架的易于制备的膦连接钯预催化剂。已经研究了前催化剂相关的不稳定卤化物（或拟卤化物）在钯环的形成和稳定性中的作用。发现用甲磺酸盐代替先前版本的预催化剂中的氯化物产生了一类具有改进的溶液稳定性并且易于从更广泛的膦配体制备的新类型的预催化剂。探讨了先前版本的 precatalyst 与此处报告的版本之间的差异。此外，后者的反应性在一系列 C-C 和 C-N 键形成反应中进行了检查。
• An Integrated Approach toward NanoBRET Tracers for Analysis of GPCR Ligand Engagement
  作者：Michael P. Killoran、Sergiy Levin、Michelle E. Boursier、Kristopher Zimmerman、Robin Hurst、Mary P. Hall、Thomas Machleidt、Thomas A. Kirkland、Rachel Friedman Ohana

  DOI：10.3390/molecules26102857

  日期：——

  Gaining insight into the pharmacology of ligand engagement with G-protein coupled receptors (GPCRs) under biologically relevant conditions is vital to both drug discovery and basic research. NanoLuc-based bioluminescence resonance energy transfer (NanoBRET) monitoring competitive binding between fluorescent tracers and unmodified test compounds has emerged as a robust and sensitive method to quantify ligand engagement with specific GPCRs genetically fused to NanoLuc luciferase or the luminogenic HiBiT peptide. However, development of fluorescent tracers is often challenging and remains the principal bottleneck for this approach. One way to alleviate the burden of developing a specific tracer for each receptor is using promiscuous tracers, which is made possible by the intrinsic specificity of BRET. Here, we devised an integrated tracer discovery workflow that couples machine learning-guided in silico screening for scaffolds displaying promiscuous binding to GPCRs with a blend of synthetic strategies to rapidly generate multiple tracer candidates. Subsequently, these candidates were evaluated for binding in a NanoBRET ligand-engagement screen across a library of HiBiT-tagged GPCRs. Employing this workflow, we generated several promiscuous fluorescent tracers that can effectively engage multiple GPCRs, demonstrating the efficiency of this approach. We believe that this workflow has the potential to accelerate discovery of NanoBRET fluorescent tracers for GPCRs and other target classes.

  获取有关配体在生物相关条件下与G蛋白偶联受体（GPCRs）相互作用的药理学见解对于药物发现和基础研究至关重要。基于NanoLuc的生物发光共振能量转移（NanoBRET）监测荧光示踪剂与未修改的测试化合物之间的竞争结合已经成为一种强大而敏感的方法，用于量化与特定GPCRs遗传融合到NanoLuc荧光酶或发光HiBiT肽的配体相互作用。然而，开发荧光示踪剂通常具有挑战性，并且仍然是该方法的主要瓶颈。减轻为每个受体开发特定示踪剂的负担的一种方法是使用多功能示踪剂，这是由BRET的固有特异性所实现的。在这里，我们设计了一种集成示踪剂发现工作流程，将机器学习引导的体外筛选具有对GPCRs显示多功能结合的支架与合成策略的混合相结合，以快速生成多个示踪剂候选物。随后，这些候选物在HiBiT标记的GPCRs库中进行了NanoBRET配体结合筛选的结合评估。利用这种工作流程，我们生成了几种可以有效与多个GPCRs相互作用的多功能荧光示踪剂，展示了这种方法的效率。我们相信这种工作流程有潜力加速发现用于GPCRs和其他靶标类别的NanoBRET荧光示踪剂。
• Identification of novel GLUT inhibitors
  作者：Holger Siebeneicher、Marcus Bauser、Bernd Buchmann、Iring Heisler、Thomas Müller、Roland Neuhaus、Hartmut Rehwinkel、Joachim Telser、Ludwig Zorn

  DOI：10.1016/j.bmcl.2016.02.050

  日期：2016.4

  The compound class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS as very potent inhibitors of facilitated glucose transporter 1 (GLUT1). Extensive structure–activity relationship studies (SAR) of each ring system of the molecular framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine). The selectivity against

  使用HTS将1 H-吡唑并[3,4- d ]嘧啶类化合物鉴定为促进葡萄糖转运蛋白1（GLUT1）的非常有效的抑制剂。建立了分子框架每个环系统的广泛结构-活性关系研究（SAR），揭示了必要的结构动机（即，邻甲氧基取代的苯，哌嗪和嘧啶）。对GLUT2的选择性非常好，并且最初的体外和体内药代动力学（PK）研究令人鼓舞。